[An Experience of S-1-Induced Rhabdomyolysis and Refractory Enteritis during Postoperative Adjuvant Chemotherapy for
Kei Yamamoto1, Yoshio Oka, Shuhei Murao
1Dept. of Surgery, Minoh City Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|February 14, 2025
Abstract:
Fluoropyrimidines are one of the key drugs in cancer chemotherapy, but rare adverse events are difficult to diagnose and treat. Here we report a case who developed the relatively rare adverse events of rhabdomyolysis and refractory enteritis during S-1-based chemotherapy for gastric cancer. Because S-1 is frequently used in daily practice of cancer chemotherapy, we should always manage adverse events with detailed knowledge of rare and potentially serious adverse events.
